Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients

Breast Cancer Research and Treatment

Volumn 101, Issue 2, 2007, Pages 185-190

  Markovitch, O ^a,b   Tepper, R ^a,b   Fishman, A ^a   Aviram, R ^a,b   Cohen, I ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

Author keywords

Aromatase inhibitors; Endometrial thickness; Tamoxifen; Ultrasound

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG WITHDRAWAL; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; POSTMENOPAUSE; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 33846294351     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9285-x     Document Type: Article

References (35)

1. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-71
2. Cohen I, Rosen DJD, Shapira J, et al (1993) Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 100:567-570
3. Lahti E, Blanco G, Kauppila A, et al (1993) Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81:660-664
4. Cohen I, Rosen DJD, Tepper R, et al (1993) Ultrasonographic evaluation of the endometrium with correlation to endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 5:275-280
5. Hulka CA, Hall DA (1993) Endometrial abnormalities associated with tamoxifen therapy for breast cancer: Sonographic and pathologic correlation. AJR 160:809-812
6. Cohen I, Rosen DJD, Shapira J, et al (1994) Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 52:185-190
7. Exacoustos C, Zupi E, Cangi B, et al (1995) Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound colour flow Doppler, hysteroscopic and histologic study. Ultrasound Obstet Gynecol 6:435-442
8. Cecchini S, Ciatto S, Bonardi R, et al (1996) Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients with tamoxifen treatment. Gynecol Oncol 60:409-411
9. Hann LE, Geiss CS, Bach AM, et al (1997) Endometrial thickness in tamoxifen-treated patients: Correlation with clinical and pathologic findings. AJR 168:657-661
10. Timmerman D, Deprest J, Bourne T, et al (1998) Randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen. Am J Obstet Gynecol 179:62-70
11. Bertelli G, Venturini M, Del Mastro L, et al (1998) Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 47:41-46
12. Love CDB, Muir BB, Scrimgeour JB, et al (1999) Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 17: 2050-2054
13. Mourits MJE, Van der Zee AGJ, Willemse PHB, et al (1999) Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen. Gynecol Oncol 73:21-26
14. Tesoro MR, Borgida AF, MacLaurin NA, et al (1999) Transvaginal endometrial sonography in postmenopausal women taking tamoxifen. Obstet Gynecol 93:363-366
15. Gerber B, Krause A, Muller H, et al (2000) Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound. J Clin Oncol 18:3464-3470
16. Hann LE, Gretz EM, Bach AM, et al (2001) Sonohysterography for evaluation of the endometrium in women treated with tamoxifen. AJR 177:337-342
17. Fong K, Kung R, Lytwyn A, et al (2001) Endometrial evaluation with transvaginal US and hysterosonography in asymptomatic postmenopausal women with breast cancer receiving tamoxifen. Radiology 220:765-773
18. Ciato S, Cecchini S, Bonardi R, et al (1994) Ultrasonographic surveillance of endometrium in breast cancer patients on adjuvant tamoxifen. Lancet 244:260
19. Goldstein SR (1994) Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 170:447-451
20. Franchi M, Ghezzi F, Donadello N, et al (1999) Endometrial thickness in tamoxifen-treated patients: an independent predictor of endometrial disease. Obstet Gynecol 93:1004-1008
21. Nahari K, Tepper R, Beyth Y, et al (1999) Long-term transvaginal endometrial follow-up in postmenopausal breast cancer patients with tamoxifen treatment. Gynecol Oncol 74:222-226
22. Cohen I, Beyth Y, Azaria R, et al (2000) Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients. Brit J Obstet Gynecol 107:1083-1087
23. Decensi A, Fontana V, Bruno S, et al (1996) Effect of tamoxifen on endometrial proliferation. J Clin Oncol 14:434-440
24. Cohen I, Azaria R, Shapira J, et al (2002) Significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women. Cancer 94:3101-3106
25. Markovitz O, Tepper R, Fishman A, et al (2004) The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 95:456-462
26. Menada MV, Papadia A, Lorenzi P, et al (2004) Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients. Eur J Gynaec Oncol 25:321-323
27. Fishman M, Boda M, Sheiner E, et al (2006) Chnages in the sonographic appearance of the uterus after discontinuation of tamoxifen therapy. J Ultrasound Med 25:469-473
28. The ATAC (Arimidex Tamoxifen Alone or in Combination) Trialists' Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359:2131-2139
29. Goss P, Ingle J, Martino S (2003) A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1-10
30. Duffy S, Jackson TL, Lansdown M, et al (2006) The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Human Reprod 21:545-553
31. Garrone O, Mezi S, Occelli M, Ortu B, Favilla A, Schere L, Bertolotti P, Rizzo A, Rinaldi M, Merlano N, Crosseto N, et al (2003) Reversal of tamoxifen induced endometrial modifications by switching to letrozole in early breast cancer patients A prospective transvaginal ultrasound study (TVUS). Ann Oncol 14 (Suppl 4):iv7 (Abstr A22)
32. Morales L, Timmerman D, Neven P, et al (2005) Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann Oncol 16:70-74
33. Berliere M, Galant C, Charles A, et al (2002) Endometrial evaluation is a very important tool in the management of breast cancer patients. Eur J Cancer (Suppl) 6:S67-S68
34. Hachisuga T, Saito T, Kigawa J, et al (2004) Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for breast cancers. Gynecol Oncol 95:139-144
35. Ferguson SE, Solow RA, Amsterdam A, et al (2006) Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol 101:322-326